Veru (NASDAQ:VERU - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01, Zacks reports. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%.
Veru Trading Up 8.7 %
Shares of VERU stock traded up $0.06 on Monday, reaching $0.79. 2,370,238 shares of the stock were exchanged, compared to its average volume of 1,602,859. The company has a market capitalization of $114.97 million, a price-to-earnings ratio of -1.66 and a beta of -0.50. The business's 50 day moving average price is $0.76 and its 200 day moving average price is $0.82. Veru has a twelve month low of $0.36 and a twelve month high of $1.92.
Analyst Upgrades and Downgrades
Separately, Oppenheimer restated an "outperform" rating and set a $5.00 price target on shares of Veru in a report on Tuesday, November 5th.
View Our Latest Research Report on VERU
Veru Company Profile
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
